(A) Total cell lysate from hVSMC was probed for TRPM7 (left panel) and EGFR (right panel) expression. Samples S1–S5 were hVSMCs derived from five different donors. (B) [Mg²⁺]_i in hVSMCs exposed to EGF (50 ng/ml) for 5 min in the absence or presence of gefitinib (Gef, 1 µM), NS8593 (NS, 40 µM) and 2-APB (30 µM). (C) ERK1/2 phosphorylation, normalized to total ERK1/2 expression, in hVSMCs exposed to EGF (50 ng/ml) for 5 min in the presence or absence of gefitinib (Gef, 1 µM), NS8593 (NS, 40 µM) and 2-APB (30 µM). (D) TRPM7 expression after 5 h treatment with EGF (50 ng/ml) in the presence and absence of gefitinib (Gef, 1 µM). (E) Cell migration assessed by Scratch-wound assay in hVSMCs treated with EGF (50 ng/ml) for 20 h in the presence or absence of gefitinib (Gef, 1 µM), PP2 (10 µM), NS8593 (NS, 40 µM), 2-APB (30 µM) and PD98059 (PD, 20 µM). Scale bar = 150 µm. Results represent the mean ± SEM of four to seven independent experiments. *P<0.05 compared with vehicle control (veh, PBS) and ^†P<0.05 compared with EGF.